title: Caffeine, adenosine receptors, and synaptic plasticity.
abstract: Few studies to date have looked at the effects of caffeine on synaptic plasticity, and those that did used very high concentrations of caffeine, whereas the brain concentrations attained by regular coffee consumption in humans should be in the low micromolar range, where caffeine exerts pharmacological actions mainly by antagonizing adenosine receptors. Accordingly, rats drinking caffeine (1 g/L) for 3 weeks, displayed a concentration of caffeine of circa 22 microM in the hippocampus. It is known that selective adenosine A1 receptor antagonists facilitate, whereas selective adenosine A2A receptor antagonists attenuate, long term potentiation (LTP) in the hippocampus. Although caffeine is a non-selective antagonist of adenosine receptors, it attenuates frequency-induced LTP in hippocampal slices in a manner similar to selective adenosine A2A receptor antagonists. These effects of low micromolar concentration of caffeine (30 microM) are maintained in aged animals, which is important when a possible beneficial effect for caffeine in age-related cognitive decline is proposed. Future studies will still be required to confirm and detail the involvement of A1 and A2A receptors in the effects of caffeine on hippocampal synaptic plasticity, using both pharmacological and genetic approaches.
authors.affiliation: Institute of Pharmacology and Neurosciences, Faculty of Medicine and Unit of Neuroscience, Institute of Molecular Medicine, University of Lisbon, Lisbon, Portugal.
authors.forename: Ana Rita
authors.initials: AR
authors.lastname: Costenla
authors.forename: Rodrigo A
authors.initials: RA
authors.lastname: Cunha
authors.forename: Alexandre
authors.initials: A
authors.lastname: de Mendonça
mesh_terms: D000367:Age Factors; D000818:Animals; D002110:Caffeine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects; D006801:Humans; D008568:Memory / Q000187:drug effects; D009473:Neuronal Plasticity / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1 / Q000378:metabolism*; D013569:Synapses / Q000187:drug effects* / Q000502:physiology
chemical_list: D010726:Phosphodiesterase Inhibitors; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D002110:Caffeine